...will buy back CCS's 75 percent stake in the company for £1.1 million ($1.8 million). OraTol...
...will return to CCS intellectual property relating to antigen delivery technology that CCS licensed to OraTol...
...CCS, which has sold its food diagnostics and laboratory services businesses, said it sold the OraTol...

...company Never formed Cortech (CRTQ) Technology in protease inhibitors European company Aug-98 Cortecs (LSE:CCS; DLVRY) OraTol...

...new companies. Flynn noted that the company had already started this process, when it created Oratol...

...OraTol Ltd., Isleworth, U.K. Business: Drug discovery Appointed: John Bienenstock, OraTol research director and professor at...

...eliminate tumor-specific DNA . . . OraTol raised £5 million (US$8.2 million) in venture financing. OraTol...
...to develop oral delivery technologies of antigens for allergies and autoimmune diseases. The financing values OraTol...

...OraTol formation, see above; financing, B14) OraTol Ltd., Isleworth, U.K. Business: Autoimmune/Inflammation Appointed: Glen Travers, chairman of...

...CCS spun off OraTol Ltd. , which will develop tolerization products to prevent and treat allergies and...
...OraTol received an exclusive worldwide license to CCS's technology for oral delivery in these fields. (OraTol...